ANIP News and Press, ANI Pharmaceuticals Inc. From 10/18/23

2023-10-18 07:02:30 ET More on ANI Pharmaceuticals ANI Pharma: Slow And Steady Revenue Generator ANI Pharma wins FDA nod for generic Estradiol tablets ANI Pharma granted FDA nod for generic Estradiol Gel For further details see: ANI Pharmaceuticals disclo...

2023-10-04 06:55:04 ET More on ANI Pharmaceuticals ANI Pharma: Slow And Steady Revenue Generator ANI Pharma wins FDA nod for generic Estradiol tablets ANI Pharma granted FDA nod for generic Estradiol Gel Seeking Alpha’s Quant Rating on ANI Pharmaceutic...

Cortrophin Gel is the only FDA-approved purified corticotropin (ACTH) indicated for the treatment of appropriate patients with acute gouty arthritis flares New 1-mL size furthers ANI’s commitment to providing ACTH options for appropriate acute gouty arthritis flare patients and the...

BAUDETTE, Minn., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Global Healthcare Conference 2023 in New York City...

2023-09-12 08:17:06 ET More on ANI Pharma Seeking Alpha’s Quant Rating on ANI Pharmaceuticals Historical earnings data for ANI Pharmaceuticals Financial information for ANI Pharmaceuticals ANI Pharma: Slow And Steady Revenue Generator ANI Pharm...

BAUDETTE, Minn., Sept. 12, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Estradiol Tablets USP. ANI’s Estradi...

2023-09-12 06:36:06 ET Summary ANI Pharmaceuticals is a revenue-generating pharmaceutical manufacturer with a low market cap. The company's rare disease segment, led by its Purified Cortrophin Gel product, is expected to be its primary growth driver. ANI Pharmaceuticals report...

2023-08-28 07:27:49 ET More on ANI ANI Pharmaceuticals, Inc. ( ANIP ) Q2 2023 Earnings Call Transcript ANI Pharmaceuticals Is Undervalued When Considering Their Unadvertised Pipeline ANI Pharmaceuticals: Strong Revenue Growth And ANDA Approvals ANI Pharma...

BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.1%. ANI’s Estradiol ...

BAUDETTE, Minn., Aug. 24, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Confere...